Physician profile
Robert L Feig
NPI 1669441101
$8,809.31
in general payments reported to CMS, 2019-2025
27 companies · $1,490 in 2025
The $1,490 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $508 · 2020: $555 · 2021: $629 · 2022: $589 · 2023: $3,150 · 2024: $1,889 · 2025: $1,490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,726 · Travel and Lodging: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,726.37 |
| Travel and Lodging | $802.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,915.62 | 2023-2024 | |
| Alcon Vision LLC | $1,239.74 | 2020-2025 | Argos, Clareon, Rocklatan |
| Bausch & Lomb Americas INC. | $1,235.78 | 2023-2025 | Envista Mx60 Iol, Xiidra, Miebo |
| Abbvie INC. | $491.72 | 2022-2025 | |
| New World Medical,INC. | $449.81 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $436.75 | 2020-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $377.89 | 2019-2023 | |
| Harrow Eye, LLC | $342.69 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $321.27 | 2022-2025 | Tyrvaya, Ryzumvi |
| Johnson & Johnson Surgical Vision, INC. | $308.41 | 2019-2025 | Tecnis Simplicity, Tecnis Iol, Tecnis Iol |
| Genentech USA, INC. | $250.53 | 2023 | Vabysmo |
| Tarsus Pharmaceuticals, INC. | $245.55 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $193.18 | 2024-2025 | Oxervate |
| Akorn Operating Company LLC | $187.04 | 2021 | |
| Eyevance Pharmaceuticals LLC | $179.12 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $132.73 | 2019-2022 | |
| Ivantis, INC | $124.37 | 2021 | |
| Allergan, INC. | $93.49 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $68.28 | 2023-2024 | Syfovre |
| Amgen INC. | $54.42 | 2025 | Tepezza |
| Eyepoint US, INC. | $38.28 | 2020 | |
| Thea Pharma INC. | $28.97 | 2023-2025 | Iyuzeh |
| Regeneron Healthcare Solutions, INC. | $21.21 | 2020 | |
| Mallinckrodt Hospital Products INC. | $20.00 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17.82 | 2020 | |
| Horizon Therapeutics Plc | $17.77 | 2022 | |
| Mallinckrodt Enterprises LLC | $16.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Feig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.